Disruption of Epithelial HDAC3 in Intestine Prevents Diet-Induced Obesity in Mice

Gastroenterology

Volumn 155, Issue 2, 2018, Pages 501-513

  Whitt, Jordan ^a   Woo, Vivienne ^a   Lee, Patrick ^a   Moncivaiz, Jessica ^a   Haberman, Yael ^a   Denson, Lee ^a   Tso, Patrick ^a   Alenghat, Theresa ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Epigenetics; Gene Regulation; Mouse Model; Overweight

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; AP4 PROTEIN; APOLIPOPROTEIN A1; BUTYRIC ACID; CARBON DIOXIDE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HEPATOCYTE NUCLEAR FACTOR 4; HISTONE DEACETYLASE 3; HOMEOBOX PROTEIN NKX-2.5; LIPID; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SHORT CHAIN FATTY ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; HISTONE DEACETYLASE;

ADIPOCYTE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY WEIGHT; BODY WEIGHT GAIN; BODY WEIGHT LOSS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DIET INDUCED OBESITY; ENERGY EXPENDITURE; GENE EXPRESSION; GLUCOSE TOLERANCE; HISTOLOGY; HUMAN; HUMAN TISSUE; ILEUM; IMPAIRED GLUCOSE TOLERANCE; INTESTINE BIOPSY; INTESTINE EPITHELIUM; JEJUNUM; METABOLISM; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SMALL INTESTINE; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; BIOPSY; C57BL MOUSE; CHILD; CYTOLOGY; DISEASE MODEL; ENERGY METABOLISM; EPITHELIUM CELL; FEMALE; GENETICS; INSULIN RESISTANCE; INTESTINE FLORA; INTESTINE MUCOSA; LIPID DIET; MALE; MICROBIOLOGY; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; BIOPSY; BODY WEIGHT; CHILD; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; EPITHELIAL CELLS; FEMALE; GASTROINTESTINAL MICROBIOME; HISTONE DEACETYLASES; HUMANS; ILEUM; INSULIN RESISTANCE; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OBESITY;

EID: 85050469860     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2018.04.017     Document Type: Article

References (55)

1. Finucane, M.M., Stevens, G.A., Cowan, M.J., et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377 (2011), 557–567.
2. Ng, M., Fleming, T., Robinson, M., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 (2014), 766–781.
3. Jiang, C., Xie, C., Lv, Y., et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun, 6, 2015, 10166.
4. Everard, A., Geurts, L., Caesar, R., et al. Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. Nat Commun, 5, 2014, 5648.
5. Sonnenburg, J.L., Backhed, F., Diet-microbiota interactions as moderators of human metabolism. Nature 535 (2016), 56–64.
6. Bäckhed, F., Ding, H., Wang, T., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A, 101(44), 2004, 15718.
7. Ley, R.E., Bäckhed, F., Turnbaugh, P., et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. Volume 102 102:31 (2005), 11070–11075.
8. Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006), 1027–1131.
9. Okubo, H., Nakatsu, Y., Kushiyama, A., et al. Gut microbiota as a therapeutic target for metabolic disorders. Curr Med Chem 25 (2017), 984–1001.
10. Gerard, P., Gut microbiota and obesity. Cell Mol Life Sci 73 (2016), 147–162.
11. Vrieze, A., Van Nood, E., Holleman, F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143 (2012), 913–916 e7.
12. Dick, K.J., Nelson, C.P., Tsaprouni, L., et al. DNA methylation and body-mass index: a genome-wide analysis. Lancet 383 (2014), 1990–1998.
13. Wahl, S., Drong, A., Lehne, B., et al. Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature 541 (2017), 81–86.
14. Macfarlane, S., Macfarlane, G.T., Regulation of short-chain fatty acid production. Proc Nutr Soc 62 (2003), 67–72.
15. Dashwood, R.H., Ho, E., Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 17 (2007), 363–369.
16. Candido, E.P., Reeves, R., Davie, J.R., Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14 (1978), 105–113.
17. Waldecker, M., Kautenburger, T., Daumann, H., et al. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem 19 (2008), 587–593.
18. Krautkramer, K.A., Kreznar, J.H., Romano, K.A., et al. Diet-microbiota interactions mediate global epigenetic programming in multiple host tissues. Mol Cell 64 (2016), 982–992.
19. Kaser, A., Niederreiter, L., Blumberg, R.S., Genetically determined epithelial dysfunction and its consequences for microflora-host interactions. Cell Mol Life Sci 68 (2011), 3643–3649.
20. Maynard, C.L., Elson, C.O., Hatton, R.D., et al. Reciprocal interactions of the intestinal microbiota and immune system. Nature 489 (2012), 231–241.
21. Ramanan, D., Cadwell, K., Intrinsic defense mechanisms of the intestinal epithelium. Cell Host Microbe 19 (2016), 434–441.
22. Bevins, C.L., Salzman, N.H., Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol 9 (2011), 356–368.
23. Alenghat, T., Osborne, L.C., Saenz, S.A., et al. Histone deacetylase 3 coordinates commensal-bacteria-dependent intestinal homeostasis. Nature 504 (2013), 153–157.
24. Navabi, N., Whitt, J., Wu, S.E., et al. Epithelial histone deacetylase 3 instructs intestinal immunity by coordinating local lymphocyte activation. Cell Rep 19 (2017), 1165–1175.
25. Feng, D., Liu, T., Sun, Z., et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 331 (2011), 1315–1319.
26. Montgomery, R.L., Potthoff, M.J., Haberland, M., et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest, 118, 2008, 10.1172/JCI35847.
27. Emmett, M.J., Lim, H.W., Jager, J., et al. Histone deacetylase 3 prepares brown adipose tissue for acute thermogenic challenge. Nature 546 (2017), 544–548.
28. Ferrari, A., Longo, R., Fiorino, E., et al. HDAC3 is a molecular brake of the metabolic switch supporting white adipose tissue browning. Nat Commun, 8, 2017, 93.
29. Sun, Z., Miller, R.A., Patel, R.T., et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat Med 18 (2012), 934–942.
30. Mullican, S.E., Gaddis, C.A., Alenghat, T., et al. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev 25 (2011), 2480–2488.
31. Madison, B.B., Dunbar, L., Qiao, X.T., et al. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem 277 (2002), 33275–33283.
32. el Marjou, F., Janssen, K.P., Chang, B.H., et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39 (2004), 186–193.
33. Haberman, Y., Tickle, T.L., Dexheimer, P.J., et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest 124 (2014), 3617–3633.
34. Alenghat, T., Meyers, K., Mullican, S.E., et al. Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 456 (2008), 997–1000.
35. Jandacek, R.J., Heubi, J.E., Tso, P., A novel, noninvasive method for the measurement of intestinal fat absorption. Gastroenterology 127 (2004), 139–144.
36. Sun, Y., Liu, S., Ferguson, S., et al. Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice. J Biol Chem 277 (2002), 23301–23307.
37. Franckhauser, S., Munoz, S., Pujol, A., et al. Increased fatty acid re-esterification by PEPCK overexpression in adipose tissue leads to obesity without insulin resistance. Diabetes 51 (2002), 624–630.
38. Yanez, A.J., Nualart, F., Droppelmann, C., et al. Broad expression of fructose-1,6-bisphosphatase and phosphoenolpyruvate carboxykinase provide evidence for gluconeogenesis in human tissues other than liver and kidney. J Cell Physiol 197 (2003), 189–197.
39. Mithieux, G., Misery, P., Magnan, C., et al. Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein. Cell Metab 2 (2005), 321–329.
40. McGee-Lawrence, M.E., Carpio, L.R., Schulze, R.J., et al. Hdac3 deficiency increases marrow adiposity and induces lipid storage and glucocorticoid metabolism in osteochondroprogenitor cells. J Bone Miner Res 31 (2016), 116–128.
41. Gonzalez, F.J., Jiang, C., Patterson, A.D., An intestinal microbiota-farnesoid X receptor axis modulates metabolic eisease. Gastroenterology 151 (2016), 845–859.
42. Fajas, L., Egler, V., Reiter, R., et al. The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell 3 (2002), 903–910.
43. Zhang, J., Henagan, T.M., Gao, Z., et al. Inhibition of glyceroneogenesis by histone deacetylase 3 contributes to lipodystrophy in mice with adipose tissue inflammation. Endocrinology 152 (2011), 1829–1838.
44. Gao, Z., Yin, J., Zhang, J., et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58 (2009), 1509–1517.
45. Lin, H.V., Frassetto, A., Kowalik, E.J. Jr., et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One, 7, 2012, e35240.
46. Whitaker, K.L., Jarvis, M.J., Beeken, R.J., et al. Comparing maternal and paternal intergenerational transmission of obesity risk in a large population-based sample. Am J Clin Nutr 91 (2010), 1560–1567.
47. Collado, M.C., Cernada, M., Bauerl, C., et al. Microbial ecology and host-microbiota interactions during early life stages. Gut Microbes 3 (2012), 352–365.
48. Cho, I., Yamanishi, S., Cox, L., et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 488 (2012), 621–626.
49. Cox, L.M., Yamanishi, S., Sohn, J., et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 158 (2014), 705–721.
50. Bailey, L.C., Forrest, C.B., Zhang, P., et al. Association of antibiotics in infancy with early childhood obesity. JAMA Pediatr 168 (2014), 1063–1069.
51. Sato, H., Zhang, L.S., Martinez, K., et al. Antibiotics suppress activation of intestinal mucosal mast cells and reduce dietary lipid absorption in Sprague-Dawley rats. Gastroenterology 151 (2016), 923–932.
52. Cani, P.D., Bibiloni, R., Knauf, C., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57 (2008), 1470–1481.
53. Shi, H., Kokoeva, M.V., Inouye, K., et al. TLR4 links innate immunity and fatty acid–induced insulin resistance. J Clin Invest 116 (2006), 3015–3025.
54. Suganami, T., Mieda, T., Itoh, M., et al. Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Biophys Res Commun 354 (2007), 45–49.
55. Lohman, R.J., Iyer, A., Fairlie, T.J., et al. Differential anti-inflammatory activity of HDAC inhibitors in human macrophages and rat arthritis. J Pharmacol Exp Ther 356 (2016), 387–396.